State Street
SANA icon

State Street’s Sana Biotechnology SANA Stock Holding History

State Street’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.1M Buy
11,203,134
+665,048
+6% +$2.14M ﹤0.01% 2000
2026
Q1 		$30.3M Buy
10,538,086
+2,483,245
+31% +$9.78M ﹤0.01% 2003
2025
Q4 		$32.8M Buy
8,054,841
+1,374,300
+21% +$6.15M ﹤0.01% 1987
2025
Q3 		$23.7M Buy
6,680,541
+3,820,417
+134% +$13.8M ﹤0.01% 2142
2025
Q2 		$7.81M Sell
2,860,124
-2,632,409
-48% -$5.43M ﹤0.01% 2736
2025
Q1 		$9.23M Sell
5,492,533
-1,217,128
-18% -$3.4M ﹤0.01% 2572
2024
Q4 		$10.9M Buy
6,709,661
+82,341
+1% +$246K ﹤0.01% 2579
2024
Q3 		$27.6M Buy
6,627,320
+269,274
+4% +$1.41M ﹤0.01% 2033
2024
Q2 		$34.7M Sell
6,358,046
-12,119
-0.2% -$96.6K ﹤0.01% 1844
2024
Q1 		$63.7M Buy
6,370,165
+461,478
+8% +$3.46M ﹤0.01% 1595
2023
Q4 		$24.1M Buy
5,908,687
+1,300,194
+28% +$4.79M ﹤0.01% 2113
2023
Q3 		$17.8M Sell
4,608,493
-229,310
-5% -$1.23M ﹤0.01% 2235
2023
Q2 		$28.8M Sell
4,837,803
-855,577
-15% -$4.93M ﹤0.01% 2006
2023
Q1 		$18.6M Sell
5,693,380
-1,095,371
-16% -$4.38M ﹤0.01% 2274
2022
Q4 		$26.8M Buy
6,788,751
+240,669
+4% +$1.18M ﹤0.01% 2035
2022
Q3 		$39.3M Sell
6,548,082
-2,046,331
-24% -$14.8M ﹤0.01% 1772
2022
Q2 		$55.3M Buy
8,594,413
+1,443,483
+20% +$9.2M ﹤0.01% 1574
2022
Q1 		$59.1M Buy
7,150,930
+3,614,591
+102% +$29.2M ﹤0.01% 1654
2021
Q4 		$54.7M Buy
3,536,339
+879,829
+33% +$17M ﹤0.01% 1743
2021
Q3 		$59.8M Buy
2,656,510
+680,068
+34% +$14.3M ﹤0.01% 1675
2021
Q2 		$38.9M Buy
1,976,442
+1,765,281
+836% +$40M ﹤0.01% 2035
2021
Q1 		$7.07M Buy
+211,161
New +$6.88M ﹤0.01% 2897

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

State Street's SANA Position: Q2 2026 in Review

State Street increased its Sana Biotechnology (SANA) stake by 6.3% in Q2 2026, buying an estimated $2.14M and bringing the position to 11,203,134 shares worth $39.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2000.

State Street first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $63.7M in Q1 2024. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • State Street held 11,203,134 shares of Sana Biotechnology worth $39.1M as of Q2 2026.
  • State Street bought 665,048 Sana Biotechnology shares in Q2 2026, an estimated $2.14M.
  • Sana Biotechnology made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2000 holding.
  • State Street first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • State Street's Sana Biotechnology position peaked at $63.7M in Q1 2024.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.